Rockville, MD, Sept. 3, 2024 (GLOBE NEWSWIRE) — According to Done.MRa provider of market research and competitive intelligence, the Global ESR Analyzer Market It is estimated that it will reach a valuation of US$ 390.0 million by 2024 and is expected to grow at a CAGR of 3.3% during the forecast period (2024 to 2034).
For the treatment of problems related to inflammation, infections, and chronic diseases, rapid and accurate diagnostic techniques are gaining increasing appeal in healthcare systems. ESR analyzers can meet this demand by providing simplified and automated procedures that dramatically shorten turnaround times for test results. The rapid response enables medical staff to make decisions about patient care and treatment plans quickly. The increasing number of people suffering from chronic diseases, such as cancer and autoimmune disorders, highlights the need for accurate diagnostic instruments that can provide consistent results.
ESR analyzers have the ability to integrate with IT systems, which ultimately increases their efficiency. This allows for seamless data management and improves patient care by integrating test results into electronic health records (EHR).
For more market insights, request a sample of this report:
Key findings from the market study
- The global ESR analyzer market is projected to grow at a rate of 3% CAGR and scope US$ 541.5 million By the year 2034
- The market created an absolute $ opportunity US$ 151.0 million growing at a CAGR of 3% Between 2024 and 2034
- North America is a major region estimated to hold a market share of 0% In 2034
- Automatic ESR analyzers are estimated to grow at a CAGR of 8% creating an absolute opportunity for US$ 110.0 million Between 2024 and 2034
- North America and Western Europe are expected to create an absolute $ opportunity US$ 72.0 million collectively
“Growing demand for advanced ESR analyzers will drive the market” says an analyst at Fact.MR.
Key players driving innovation in the ESR Analyzers Market:
Spanish: Streck, Inc.; ALIFAX Srl; R.R. Mechatronics; Polymedco, LLC.; Caretium Medical Instruments Co., Limited; Beckman Coulter, Inc.; Greiner Group (Greiner Bio One International GmbH); ALCOR Scientific Inc.; Diesse Diagnostica Senese Spa; ELITechGroup; Perlong Medical; Biolab Scientific; Beijing Successor Technology Inc.; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; SFRI Medical Diagnostics.
Market development
Erythrocyte sedimentation rate (ESR) testing has shown a promising change in recent years. The transition of ESR testing from manual to automated is one of the most notable achievements. Automated systems are rapidly replacing the Westergren technique and other traditional manual procedures due to their standardized results, reduced human error, and increased efficiency. For example, Diesse Diagnostica Senese has developed a Ves-Matic Cube 200 analyzer with the capacity to process up to 200 samples per hour.
The development of ESR analyzers has focused attention on the areas of portability and minimization. This trend is best illustrated by ALCOR Scientific’s iSED, a small, fully automated analyzer that can be used for point-of-care testing. Multi-parameter testing capabilities are becoming common in advanced ESR analyzers. RR Mechatronics’ Starrsed ST analyzer offers a more comprehensive assessment of inflammation by combining the ability to perform ESR and C-reactive protein (CRP) assays from a single sample.
ESR Analyzer Industry News:
- Horiba introduced a new line of hematology analyzers in June 2024: Yumizen H550E (autoloader), Yumizen H500E CT (closed tube), and Yumizen H500E OT (open tube) with combined ESR and CBC/Diff testing. These functions are now integrated into Horiba analyzers by using “CoRA” (correlated rouleaux analysis) technology.
- The innovative BC-700 series of hematology analyzers, introduced by Mindray (Shenzhen, China) in March 2022, enables both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) testing. Mid-volume laboratories will be able to more easily apply cutting-edge diagnostic solutions for their high-end products with this series of tools.
- ESR analyzers are among the diagnostic products for which Alifax is renowned. The distinctive features incorporated into the company's ESR analyzers enable fast and accurate analysis.
- High-performance ESR analyzers for clinical laboratories are designed by Beckman Coulter. The company offers more operationally efficient systems.
Get customization of this report for specific research solutions:
More valuable information on offer
Fact.MR, in its new offering, presents an unbiased analysis of the global ESR analyzer market, featuring historical data from 2019 to 2023 and forecast statistics for 2024 to 2034.
The study reveals essential information on the basis of product type (automated ESR analyzer, semi-automated ESR analyzer, and manual ESR analyzer), modality (portable ESR analyzer and benchtop ESR analyzer), end-user (hospitals and clinics, diagnostic laboratories, contract research organizations, academic and research institutes, and blood banks) across major regions of the world (North America, Latin America, Western Europe, Eastern Europe, Eastern Asia, South Asia & Pacific, and Middle East & Africa).
See more related studies published by Fact.MR Research:
Blood gas and electrolyte analyzers marketThe global blood gas and electrolyte analyzers market size is expected to grow from a valuation of 4.7 billion US dollars in 2024 to 7.82 billion US dollars by 2034, increasing at a rate CAGR of 5.2% until the year 2034.
Analysis of laboratory information management system Fact.MR report shows that global laboratory information management system revenue in 2021 remained at US$ 1.8 billion. With 8.1%, he projected market growth during 2022 – 2032
eCOA, eSource and the Clinical Trials Market: He Global eCOA, eSource and Clinical Trials Market is valued at 48 billion dollars by 2023 and is expected to reach a market size of 104 billion dollars By the end of 2033, expanding rapidly at a CAGR of 8% in the next ten years.
Non-invasive aesthetic treatments market: is approaching an increase in 20.7% CAGR and reach 260 billion dollars by the end of 2034.
Treponema pallidum test market: It is analyzed to increase up to a value of US$ 360 million By the end of 2034, expanding at a rate CAGR of 5.8%.
About us:
Done.MR is a distinguished market research firm recognized for its comprehensive market reports and valuable business insights. As a leading player in business intelligence, we offer in-depth analysis that reveals market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we provide businesses with crucial data and strategic recommendations, facilitating informed decision-making and improving market positioning.
With its unwavering dedication to providing reliable market insights, FACT.MR continues to help businesses face dynamic market challenges with confidence and achieve long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures that its clients receive actionable insights to take advantage of emerging opportunities and stay competitive.
Follow us: LinkedIn | Twitter | Blog
Contact: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 Sales Team: sales@factmr.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.